Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

Dow Jones
2025/11/20

0929 ET - Abbott's acquisition of Exact Sciences could help revitalize Abbott's diagnostics business, TD Cowen analyst Joshua Jennings said in a report issued shortly before the deal was formerly announced earlier today. Jennings believes integrating Exact would add roughly 2.5 percentage points of incremental organic growth to Abbott's diagnostics segment during the early post-deal period, "essentially restoring the franchise to its historical baseline before pandemic distortions emerged." The acquisition would also likely provide a roughly 50 basis point boost to the entire company's organic revenue growth, a meaningful acceleration for a company of Abbott's scale. (nicholas.miller@wsj.com)

(END) Dow Jones Newswires

November 20, 2025 09:30 ET (14:30 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10